A hemp retailer can hold a current certificate of analysis on every SKU, pass every compliance audit, and still receive a processor termination notice with no warning and no real explanation. The product is federally legal under the 2018 Farm Bill. The sales are legitimate. The bank closes the account anyway. That gap - between a lawful operation and a financial system that refuses to serve it - is the operating reality for most CBD sellers right now, and it has almost nothing to do with how carefully those sellers run their stores.
The mechanism behind this is association, not evidence. Hemp-derived CBD comes from the same plant as marijuana, and that proximity is enough for most acquiring banks and card networks to fold the entire category into a single high-risk bucket. A compliance officer reviewing a merchant portfolio rarely stops to parse the difference between a 0.3% THC hemp extract and a Schedule I controlled substance - the cautious move is to decline the whole class and move on. Retailers operating in tightly regulated markets have long dealt with adjacent compliance pressures; dispensaries in states like Alaska that use cannabis pos software alaska to manage seed-to-sale tracking and state reporting requirements understand how quickly a category label can override a clean operational record, regardless of what the compliance logs actually show. For CBD sellers, the logic is the same: a spotless COA does not undo a reputation built on proximity to a banned drug.
The FDA has compounded the problem rather than resolved it. The 2018 Farm Bill handed hemp a federal legal status, but the FDA still bars CBD from foods and dietary supplements under existing food-additive rules, and it has approved exactly one cannabidiol product - the seizure medication Epidiolex. Everything else sits in a regulatory gray zone that banks read as live liability. The agency has sent a steady stream of warning letters to sellers making health claims, and banks treat that enforcement activity as a signal that the whole category is exposed. Until federal guidance settles, processors either price the uncertainty into every CBD account or decline the category outright. Most choose the latter.
Operation Choke Point Left a Habit Banks Still Follow
Some of what's happening now traces back further than 2018. Starting in 2013, a federal initiative called Operation Choke Point pressured banks to sever ties with industries regulators considered high risk - firearms dealers, payday lenders, and others. The program ended formally in 2017, but the institutional reflex it created did not. Banks learned that servicing a flagged category invites regulatory scrutiny, so many adopted blanket de-risking policies: refuse entire sectors rather than evaluate merchants one by one. CBD inherited that reflex even after its legal footing improved. The result is that a clean compliance record often counts for less than the product category label itself - and that's not a solvable problem at the merchant level.
The legislative fix keeps stalling. The SAFER Banking Act, which would extend federal protections to banks that serve state-legal cannabis businesses and adjacent industries, has cleared the House and advanced through committee more than once. It has never passed the full Senate. Without that statutory cover, banks have no federal protection for the risk they absorb by serving the category, so the safe answer remains no. A federal rescheduling move for cannabis could ease some of the surrounding pressure, but the banking bill itself sits parked under leadership that has shown little interest in advancing it.
The Chargeback Loop Makes the Category's Numbers Work Against It
The category's own dispute rates reinforce the caution. CBD sees elevated chargebacks relative to most retail - partly because buyers don't always recognize the charge descriptor on a statement, and partly because impulse purchases get regretted. Every chargeback above card network thresholds pushes an account closer to termination and confirms the high-risk classification the merchant is trying to shed. Here's the catch: banks expect trouble, price for it or decline, and the friction that follows produces the instability they feared, which then becomes the evidence the next processor cites when refusing to onboard. The loop is self-sustaining.
Even accounts that survive initial underwriting rarely run on standard terms. Processors typically impose a rolling reserve - holding back a share of each settlement batch, often in the range of five to ten percent, for months before releasing it. That ties up working capital a growing store needs for inventory replenishment. Worse, a nervous processor can freeze an account mid-review and hold the full balance, leaving a seller unable to pay suppliers while the money sits inaccessible. The threat of a freeze, more than the headline rate, is what makes mainstream processing structurally unreliable for this category. It pushes sellers toward specialists who price for stability rather than surprising them with an account suspension during their highest-volume month.
Specialists Exist Because the Mainstream Won't Adapt
The workable answer, for most CBD sellers, is a processor that specializes in the category - not because those providers are lenient, but because they've underwritten the risk deliberately and built it into their pricing from the start. A generalist may onboard a CBD store and then drop it the moment an automated review flags the product type. A specialist has already modeled the category's dispute profile, set appropriate reserve requirements, and established limits that reflect actual volume patterns rather than a generic retail benchmark. That stability carries real economic value - more, in most cases, than a slightly lower processing rate that evaporates the moment the account is frozen.
To put it plainly: the problem facing most hemp CBD retailers isn't compliance failure. It's a financial system that moves slower than the law that governs the products being sold. Hemp became federally legal in 2018. The regulatory framework banks answer to - the FDA's unresolved guidance, the unfinished banking legislation, the institutional habits left by years of de-risking policy - has not caught up. Most CBD sellers are lawful operators caught in someone else's caution. Until Congress acts or the FDA settles its position, the path to reliable payment processing runs through the providers that have already chosen to understand this category, and the choice of processor will continue to determine whether a legal product can actually collect the revenue it earns.
